Lupus & antiphospholipid syndrome
Severe infections in patients with systemic lupus erythematosus from Tunisia: Prevalence and risk factors
Study context
- Population
- Tunisian SLE patients followed between 2010 and 2019; mean age of the disease 33.63 ± 13.76 years
- Participants
- 93 patients
- Outcome
- Prevalence and risk factors of severe infections
Main finding
As reported in the abstract
Severe infections, prevalence
Patients with infections (118 infections in total)
52
Infections that were serious
16%
Observational data: associations, not effects.
Further findings
Antimalarial use and severe infection (protective effect)
| OR (95% CI) | P value | ||
|---|---|---|---|
| Antimalarial use | 0.19 (0.03–0.9) | P < 0.03 | |
| 0.050.21520Odds ratio (log scale) |
Total cumulative GC dose and number of serious infections (bivariate analysis)
- Positive correlation
- P = 0.009
Independent risk factors of severe infections (multivariate analysis)
- Number of flares
- P = 0.03
- Pulmonary manifestations
- P = 0.01
- Pleuritis
- P = 0.001
- Total cumulative GC dose
- P = 0.04
- Overall model
- P < 0.001
Original publication
Severe infections in patients with systemic lupus erythematosus from Tunisia: Prevalence and risk factors. Lupus. Published 21 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →